newsfilter
← Earnings
Earnings Releases·

Moleculin Biotech — Third Quarter 2026 Earnings Summary

  • Revenue remained $0 for the three and nine months ended September 30, 2026, while net loss narrowed to $6.5 million for the quarter (down from $25.4 million in 2025) and $27.0 million for the nine months (down from $49.1 million in 2025), primarily driven by the absence of a $20.6 million non-cash warrant liability loss recorded in the prior year.
  • R&D expenses increased to $4.5 million for the quarter and $15.3 million for the nine months compared to $3.7 million and $10.8 million respectively in the prior year periods, contributing to a cash balance decline to $7.3 million as of September 30, 2026.
  • The MIRACLE trial Part A treatment for relapsed/refractory AML is complete with 90 patients, and comprehensive data is on track for release in Q1 2027, with Part B initiation planned for the first half of 2027.
  • The Company faces a critical financing gap with no committed funding for required clinical trials, necessitating significant additional capital to proceed with the 2028 NDA submission timeline.
Company
MOLECULIN BIOTECH INC
Sector
Healthcare
Industry
Biotechnology